11-12 September 2018 //  Lancaster Royal Hotel, London


Mark de Boer

Dr Mark de Boer

CEO, Gadeta

Dr. Mark de Boer (CEO) is an independent serial biotech entrepreneur and founded several successful biotech companies. He is a Venture Partner at Medicxi Ventures, the recent Life Science spin-off from Index Ventures.  Mark joined Index Ventures in 2005 and his investments include Comentis, Molecular Partners, PanGenetics (acquired by Abbott), ProFibrix (acquired by The Medicines Company) and Versartis. He is also an advisor to the Utrecht University Technology Transfer Office and Holdings. Mark graduated in Biochemistry and has a PhD from the University of Amsterdam. He has worked for, managed and founded a number of early-stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad